Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism.

Martijn P. Lolkema,Elizabeth Ruth Plummer,Filip de Vos,Martin Forster,Eric Angevin,Marion Libouban,Ellen Jansen,Marc Tjwa,Eric Ciamporcero,Ann Meulemans,Annegret Van der Aa,Timothy Pietro Suren Perera,Glen Clack,Matthew G Krebs,Sarah P. Blagden

Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism.

2019

Martijn P. Lolkema
Elizabeth Ruth Plummer
Filip de Vos
Martin Forster
Eric Angevin
Marion Libouban
Ellen Jansen
Marc Tjwa
Eric Ciamporcero
Ann Meulemans
Annegret Van der Aa
Timothy Pietro Suren Perera
Glen Clack
Matthew G Krebs
Sarah P. Blagden

3062Background: MET kinase is a therapeutic target in a range of cancer indications; it is a primary oncogenic driver and a mechanism of therapy resistance. OMO-1 is a highly potent, selective oral...

Keywords:

Modular design
Physical therapy
Clinical trial
Kinase
Oncology
Medicine
Internal medicine
in patient
treatment resistance
Cancer
Pathology
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations